Additional Details

  • A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

    Clinical Site Partners, LCC
    Leesburg FL. 34748
    View Details

  • H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

    NIEHS Clinical Research Unit (CRU)
    Research Triangle Park NC. 27709
    View Details

  • The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

    University of Virginia
    Charlottesville VA. 22908
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

    Southeastern Research Center
    Winston Salem NC. 27103
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

    MUSC Pulmonary Research
    Charleston SC. 29425
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

    Montefiore Medical Center
    Bronx NY. 10467
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

    Mayo Clinic
    Jacksonville FL. 32224
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF

    Newport Native MD, Inc.
    Newport Beach CA. 92663
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Saint Petersburg FL. 33704
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Vancouver V5Z 1M9
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Hamilton L8N 4A6
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Wilmington NC. 28401
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Newport Beach CA. 92663
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Philadelphia PA. 19140
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Trois RiviEres G8T 7A1
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    New York NY. 10065
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Ajax L1S 2J5
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Jacksonville FL. 32224
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Cypress TX. 77429
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Nashville TN. 37204
    View Details